[Correspondence] Rethinking CLDN18.2 expression in gastric cancer therapy – Authors' reply

We thank Peng Luo and colleagues for their interest in our work and insightful Correspondence regarding our Article on satricabtagene autoleucel (satri-cel).1 Their points on the dynamic nature of claudin-18 isoform 2 (CLDN18.2) expression and the effect of tumour biological heterogeneity are well received and resonated with broader challenges in the field of chimeric antigen receptor (CAR) T-cell therapy in solid tumours.